• CP-673451: Selective PDGFRα/β Inhibitor Workflows

  2026-09-03

  CP-673451 enables focused interrogation of PDGFR-α/β signaling, PDGF-BB-driven angiogenesis, and tumor biology with less interference from several neighboring kinases. This practical guide connects phospho-signaling assays, ATRX-stratified glioma experiments, and xenograft readouts to reproducible workflow and troubleshooting decisions.

• Abiraterone acetate in 3D Prostate Cancer Models

  2026-09-02

  Use Abiraterone acetate as a controlled CYP17 inhibitor probe in patient-derived prostate spheroids, where drug penetration, androgen signaling, and tumor heterogeneity can be evaluated together. The workflow below combines formulation-aware handling with orthogonal viability, PSA, immunohistochemistry, and androgen receptor readouts.

• Hoechst 33342 for Live-Cell Nuclear Imaging

  2026-09-02

  Hoechst 33342 supports consistent nuclear segmentation across live-cell imaging, fixed-cell immunofluorescence, and flow cytometry workflows. This practical guide shows how to use the 1 mg/mL reagent to strengthen dermal fibroblast senescence assays without treating nuclear fluorescence as a standalone biological endpoint.

• ATP Workflows for OGDH Metabolism Research

  2026-09-02

  Use ATP to connect mitochondrial enzyme activity, proteostasis, and purinergic signaling in experimentally controlled workflows. This guide translates the TCAIM–OGDH discovery into practical ATP titrations, native-protein assays, extracellular stimulation studies, and troubleshooting decisions.

• Mitochondrial Calcium Signaling Represses Ferroptosis

  2026-09-01

  The reference study identifies mitochondrial calcium uptake through MCU as a regulator of ferroptosis resistance, linking mitochondrial acetyl-CoA production to GPX4 acetylation and activity. Genetic and structural evidence further connects this pathway to tumor growth, providing a mechanistic framework for studying how mitochondrial metabolism shapes lipid-peroxide defense.

• Sildenafil Citrate: Vascular Signaling Workflows

  2026-08-31

  Build reproducible PDE5 experiments that connect cGMP accumulation with vascular smooth muscle relaxation, ERK signaling, and functional tissue responses. This guide also shows how to extend conventional cell assays toward proteoform-aware native membrane studies while avoiding common solubility, vehicle, and off-target interpretation errors.

• Lipid Peroxidation (MDA) Assay Kit Workflow

  2026-08-31

  Build a reliable malondialdehyde workflow for tissue, cell, plasma, serum, and urine samples using matched colorimetric and fluorescence readouts. This guide connects MDA quantification to ferroptosis and sepsis-associated kidney injury while emphasizing matrix control, calibration, and troubleshooting.

• Balsalazide disodium in IBD research

  2026-08-30

  Balsalazide disodium enables researchers to connect colonic bacterial activation with localized 5-aminosalicylic acid biology. This guide turns that mechanism into practical workflows for inflammation research, immunology assays, and inflammatory bowel disease models, with concentration planning and troubleshooting guidance.

• Vemurafenib (PLX4032) Melanoma Workflow

  2026-08-29

  Build more informative BRAF-mutant melanoma experiments with Vemurafenib (PLX4032), from concentration-response assays to time-resolved resistance profiling. This workflow pairs pathway pharmacology with ARID1A-aware multi-omics design to distinguish on-target response, adaptive signaling, and stable resistance.

• AAL-993: VEGF Receptor Inhibitor to Translation

  2026-08-28

  A mechanistic and translational framework for using AAL-993 to connect VEGF receptor blockade, angiogenesis biology, melanoma models, and network-informed glioma research.

• CP-673451: From PDGFR Potency to Assay Insight

  2026-08-28

  CP-673451 is a selective PDGFRα/β inhibitor for dissecting receptor phosphorylation, angiogenesis, and tumor biology. This article presents an assay-centered framework that connects its pharmacology with ATRX-aware glioma research while defining practical controls and translational limits.

• Reversine: Practical Aurora Kinase Inhibitor Workflow

  2026-08-28

  Reversine (SKU A3760) provides a research tool for probing Aurora kinase-dependent mitotic regulation, cell-cycle disruption, and related cancer-cell phenotypes. This guide covers solution preparation, assay controls, QC, and interpretation; it is intended for research use only and does not establish clinical, diagnostic, or universal cellular dosing recommendations.

• Nigericin: Potassium/Hydrogen Ion Carrier Workflows

  2026-08-27

  Nigericin converts potassium–proton exchange into a practical tool for intracellular pH modulation, mitochondrial membrane ion transport, viability testing, and GSDMD-linked cell-death studies. This workflow-focused guide also explains how metabolic findings from antibiotic-resistance research can inform, but not overstate, new Nigericin assay designs.

• TMEM16F, Ferroptosis, and Tumor Immunity

  2026-08-26

  Yang et al. identify TMEM16F-mediated plasma-membrane lipid scrambling as an execution-stage brake on ferroptosis. Loss of this response promotes lytic membrane failure and danger signaling, while combining scrambling inhibition with PD-1 blockade strengthens tumor immune rejection.

• Propranolol and Essential Tremor Mechanisms

  2026-08-26

  A prospective TMS study links propranolol’s tremor benefit in essential tremor to reduced corticospinal excitability and enhanced afferent inhibition, supporting a central noradrenergic–GABAergic mechanism alongside peripheral β-adrenergic effects. The findings also show how neurophysiological measures can distinguish the mechanisms of propranolol from those of primidone and inform future essential tremor therapy research.

8527 records 1/569 page Next 12345 下5页 Last page